Details of the Drug Combination

General Information of Drug Combination (ID: DCF45XK)

Drug Combination Name
Plerixafor Clofarabine
Indication
Disease Entry Status REF
Acute Myelogenous Leukemia Phase 1 [1]
Component Drugs Plerixafor   DMCJN1P Clofarabine   DMCVJ86
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Plerixafor
Disease Entry ICD 11 Status REF
Non-hodgkin lymphoma 2B33.5 Approved [2]
Plerixafor Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
C-X-C chemokine receptor type 4 (CXCR4) TTBID49 CXCR4_HUMAN Antagonist [5]
------------------------------------------------------------------------------------
Plerixafor Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Stromal cell-derived factor 1 (CXCL12) OT2QX5LL SDF1_HUMAN Decreases Expression [6]
------------------------------------------------------------------------------------
Indication(s) of Clofarabine
Disease Entry ICD 11 Status REF
Acute lymphoblastic leukaemia 2A85 Approved [3]
Acute myelogenous leukaemia 2A41 Approved [4]
Langerhans cell histiocytosis N.A. Approved [4]
Leukemia N.A. Approved [4]
Myelodysplastic syndrome 2A37 Approved [3]
Plasma cell myeloma 2A83.1 Approved [4]
Classic Hodgkin lymphoma N.A. Investigative [4]
Clofarabine Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Bacterial Penicillin binding protein (Bact PBP) TTJP4SM NOUNIPROTAC Binder [7]
Ribonucleotide reductase (RIR) TTX09M4 RIR1_HUMAN; RIR2_HUMAN; RIR2B_HUMAN Inhibitor [7]
------------------------------------------------------------------------------------
Clofarabine Interacts with 4 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [8]
Concentrative Na(+)-nucleoside cotransporter 3 (SLC28A3) DT4YL5R S28A3_HUMAN Substrate [9]
Equilibrative nucleoside transporter 1 (SLC29A1) DTXD1TQ S29A1_HUMAN Substrate [9]
Equilibrative nucleoside transporter 2 (SLC29A2) DTW78DQ S29A2_HUMAN Substrate [9]
------------------------------------------------------------------------------------
Clofarabine Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Deoxycytidine kinase (DCK) DE9FGNK DCK_HUMAN Metabolism [10]
------------------------------------------------------------------------------------
Clofarabine Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Affects Activity [11]
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) OT2YYI1A MCL1_HUMAN Decreases Expression [12]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01160354) Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML)
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 844).
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6802).
4 Clofarabine FDA Label
5 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
6 Inhibition of CXCL12/CXCR4 autocrine/paracrine loop reduces viability of human glioblastoma stem-like cells affecting self-renewal activity. Toxicology. 2013 Dec 15;314(2-3):209-20. doi: 10.1016/j.tox.2013.10.003. Epub 2013 Oct 21.
7 Clofarabine: past, present, and future. Leuk Lymphoma. 2007 Oct;48(10):1922-30.
8 Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides. Mol Cancer Ther. 2008 Sep;7(9):3092-102.
9 Cytarabine-resistant leukemia cells are moderately sensitive to clofarabine in vitro. Anticancer Res. 2014 Apr;34(4):1657-62.
10 FDA label of Belinostat. The 2020 official website of the U.S. Food and Drug Administration.
11 Identification of environmental chemicals that activate p53 signaling after in vitro metabolic activation. Arch Toxicol. 2022 Jul;96(7):1975-1987. doi: 10.1007/s00204-022-03291-5. Epub 2022 Apr 18.
12 Knockdown of Bcl-xL enhances growth-inhibiting and apoptosis-inducing effects of resveratrol and clofarabine in malignant mesothelioma H-2452 cells. J Korean Med Sci. 2014 Nov;29(11):1464-72. doi: 10.3346/jkms.2014.29.11.1464. Epub 2014 Nov 4.